Peptide therapy with Ipamorelin and CJC-1295 is gaining traction for its ability to boost muscle growth, fat loss, and overall wellness
His work focuses on how microbial ecosystems interact with human physiology, including: Gut barrier function and intestinal permeability Mucus-associated microbiota (Akkermansia-related systems) Oralgut microbiome axis Short-chain fatty acids (SCFAs) and metabolic signaling Circadian rhythmmicrobiome interactions Clinical Research Contributions He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including: Active Ulcerative Colitis (Inflammatory Bowel Disease) Hyperoxaluria (Oxalate Metabolism Disorder) Microbiome-driven gut health and inflammatory conditions These studies were part of broader clinical development programs evaluating microbiome-based approaches
Piening A, Ebert E, Gottlieb C, Khojandi N, Kuehm LM, Hoft SG, et al
Consistency is key for seeing the best results